Long, Georgina V <br/><br/>
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAF  [electronic resource] 

 -  The Lancet. Oncology  07 2019 
 - 961-971 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-5488 
<br/><br/><label>Standard No.: </label>10.1016/S1470-2045(19)30331-6  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Female<br/>Humans<br/>Imidazoles--administration & dosage<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Mutation<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Oximes--administration & dosage<br/>Proto-Oncogene Proteins B-raf--genetics<br/>Pyridones--administration & dosage<br/>Pyrimidinones--administration & dosage<br/>Skin Neoplasms--drug therapy